OverviewSuggest Edit

Opiant Pharmaceuticals is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. Opiant Pharmaceuticals is also focused on other treatment opportunities.

TypePublic
Founded2009
HQSanta Monica, US
Websiteopiant.com

Latest Updates

Employees (est.) (Mar 2020)21(+32%)
Revenue (FY, 2019)$40.5 M(+190%)
Share Price (Sept 2020)$8.9 (+2%)
Cybersecurity ratingAMore

Key People/Management at Opiant Pharmaceuticals

Roger Crystal

Roger Crystal

President, Chief Executive Officer, Director
Ann MacDougall

Ann MacDougall

Independent Director
Craig Collard

Craig Collard

Independent Director
Phil Skolnick

Phil Skolnick

Chief Scientific Officer
Mark Ellison

Mark Ellison

Chief Development Officer
Gabrielle A. Silver

Gabrielle A. Silver

Lead Independent Director
Show more

Opiant Pharmaceuticals Office Locations

Opiant Pharmaceuticals has offices in Santa Monica and London
Santa Monica, US (HQ)
233 Wilshire Blvd #280
Santa Monica, US
401 Wilshire Blvd 12th Floor
London, GB
One Kingdom St, Paddington
Show all (3)

Opiant Pharmaceuticals Financials and Metrics

Opiant Pharmaceuticals Revenue

Opiant Pharmaceuticals's revenue was reported to be $40.52 m in FY, 2019
USD

Revenue (Q2, 2020)

6.3m

Net income (Q2, 2020)

(216.2k)

EBIT (Q2, 2020)

(231.6k)

Market capitalization (17-Sept-2020)

38.1m

Closing stock price (17-Sept-2020)

8.9

Cash (30-Jun-2020)

30.5m

EV

8.0m
Opiant Pharmaceuticals's current market capitalization is $38.1 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

18.4m14.0m40.5m

Revenue growth, %

(24%)

Cost of goods sold

Gross profit

40.5m
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

13.5m18.1k22.0k1.7m3.2m4.4m5.4m6.8m20.6m4.3m6.3m

Cost of goods sold

Gross profit

6.8m20.6m

Gross profit Margin, %

100%100%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

20.4k598.6k254.8k434.2k1.5m8.1m24.6m31.0m

Accounts Receivable

312.5k11.7m4.5m

Prepaid Expenses

733.3k1.1m

Current Assets

20.4k619.9k278.8k467.4k1.9m20.8m29.4m39.3m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

12.6k47.4k25.0k2.2k151.7k609.9k323.7k420.4k180.8k1.1m1.1m1.3m455.2k1.3m2.4m1.2m12.9m9.7m5.9m11.3m11.2m24.8m23.8m23.9m23.2m32.2m30.5m

Accounts Receivable

699.1k3.0m2.0m4.3m16.1m4.2m

Prepaid Expenses

534.5k729.0k737.0k560.0k346.0k522.0k493.0k940.0k1.0m

Current Assets

12.6k47.4k25.0k2.2k151.7k639.7k336.5k424.7k222.5k1.7m1.1m1.4m473.0k1.3m2.4m2.0m13.0m9.8m6.8m13.7m14.8m29.3m26.2m28.8m40.2m37.4m38.7m
USDQ1, 2012

Financial Leverage

-0.2 x
Show all financial metrics

Opiant Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Opiant Pharmaceuticals Online and Social Media Presence

Embed Graph

Opiant Pharmaceuticals Blogs

Opiant Pharmaceuticals to Report Fourth Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, March 4

SANTA MONICA, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fourth quarter and year

Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose

Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose Content Import Thu, 01/02/2020 - 08:01 Opiant Pharmaceuticals Announces Development Collaborat…

Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose Content Import Thu, 12/12/2019 - 16:05 Opiant Ph…

Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

SANTA MONICA, Calif. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the third quarter and nine months ended September 30,

Opiant Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on Tuesday, November 12

SANTA MONICA, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the third quarter and nine

Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

SANTA MONICA, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that it will present at the 2019 Cantor Global Healthcare Conference , taking
Show more

Opiant Pharmaceuticals Frequently Asked Questions

  • When was Opiant Pharmaceuticals founded?

    Opiant Pharmaceuticals was founded in 2009.

  • Who are Opiant Pharmaceuticals key executives?

    Opiant Pharmaceuticals's key executives are Roger Crystal, Ann MacDougall and Craig Collard.

  • How many employees does Opiant Pharmaceuticals have?

    Opiant Pharmaceuticals has 21 employees.

  • What is Opiant Pharmaceuticals revenue?

    Latest Opiant Pharmaceuticals annual revenue is $40.5 m.

  • What is Opiant Pharmaceuticals revenue per employee?

    Latest Opiant Pharmaceuticals revenue per employee is $1.9 m.

  • Who are Opiant Pharmaceuticals competitors?

    Competitors of Opiant Pharmaceuticals include IntelGenx, Vitality Biopharma and Horizon Therapeutics.

  • Where is Opiant Pharmaceuticals headquarters?

    Opiant Pharmaceuticals headquarters is located at 233 Wilshire Blvd #280, Santa Monica.

  • Where are Opiant Pharmaceuticals offices?

    Opiant Pharmaceuticals has offices in Santa Monica and London.

  • How many offices does Opiant Pharmaceuticals have?

    Opiant Pharmaceuticals has 3 offices.